Compounded Semaglutide vs Wegovy: Key Differences in Safety, Cost and Results

Wegovy is an FDA-approved 2.4 mg once-weekly semaglutide injection that helped adults lose an average 14.9% of body weight in the STEP 1 trial, while “compounded semaglutide” is a pharmacy-mixed version that has never been reviewed by the FDA for safety, quality or effectiveness. Wegovy contains the base form of semaglutide in single-use pens; compounded products may use unapproved salt forms, multi-dose vials and non-standard strengths. Because the two are regulated differently, they differ in reliability, legal status and out-of-pocket cost.

• Wegovy won FDA approval for chronic weight management on June 4 2021 after a 68-week trial showed 14.9% mean weight loss versus 2.4% with placebo. (accessdata.fda.gov)
• Compounded semaglutide is not FDA-approved; the FDA has warned of potency problems, use of untested salt forms and dosing errors. (fda.gov)
• The Wegovy list price is $1,349.02 for a four-week supply, though Medicare’s new GLP-1 Bridge caps many beneficiaries’ cost at $50 per month starting July 2026. (drugs.com)
• Compounded semaglutide from licensed 503A/503B pharmacies typically costs $231–$330 per month, while the Rx.com weight loss program offers compounded semaglutide from $99 per month with a 12-month plan. (jamanetwork.com)
• FDA declared the nationwide semaglutide shortage resolved in February 2025, meaning most compounding is now considered “essentially a copy” of an approved drug and subject to enforcement. (fda.gov)

What Wegovy and compounded semaglutide are in plain English

Wegovy is… an FDA-approved, once-weekly injectable form of semaglutide (2.4 mg maximum dose) specifically labeled for chronic weight management in adults and teens with obesity or overweight plus at least one weight-related condition. (accessdata.fda.gov)

Compounded semaglutide is… a custom-mixed preparation of semaglutide made by a licensed compounding pharmacy when the FDA lists the drug on its shortage list or when a prescriber needs a formulation that is “not commercially available.” It is not FDA-reviewed and may use different salt forms (acetate or sodium) or be combined with vitamin B12, which the agency considers “essentially a copy” of Wegovy once shortages are resolved. (fda.gov)

Both products work as GLP-1 receptor agonists, signaling the brain’s appetite centers, slowing stomach emptying and reducing food cravings. (medlineplus.gov) However, only Wegovy’s exact formulation has been proven in large clinical trials.

How lack of FDA approval changes quality, labeling and legality

FDA gold standard: Wegovy underwent rigorous chemistry, manufacturing, controls and clinical testing before approval. Every pen is produced in a Novo Nordisk facility that meets Good Manufacturing Practice (GMP) standards. (accessdata.fda.gov)

Compounded gray zone: Compounded products are regulated primarily by state boards of pharmacy. They do not submit stability data, sterility testing or human trial results to the FDA. The agency has issued multiple warning letters about compounded semaglutide containing the wrong salt form, particulate contamination or incorrect dosage markings. (fda.gov)

How effective is each option for weight loss?

Wegovy’s evidence: In the 68-week STEP 1 trial of 1,961 adults, participants lost a mean 14.9% of their starting weight on Wegovy compared with 2.4% on placebo. One in three people lost at least 20% of body weight. (nejm.org)

Compounded semaglutide’s evidence: No randomized controlled trials have evaluated any compounded semaglutide formulation. Reported weight-loss numbers on social media or small clinic surveys are anecdotal and may not match pharmaceutical-grade Wegovy results.

Safety and ingredient quality: what the FDA and research say

Known Wegovy risks: nausea, vomiting, gallstones and a boxed warning about thyroid C-cell tumors observed in rodents. (accessdata.fda.gov)

Extra compounded risks: The FDA has logged adverse events tied to compounded semaglutide including severe nausea from dosing errors, injection-site abscesses due to contamination, and under-dosing leading to lack of effect. (fda.gov)

Salt-form uncertainty: Wegovy uses the semaglutide base; compounded versions that substitute semaglutide acetate or sodium have never been proven bioequivalent. The FDA warns these are “different active ingredients.” (fda.gov)

Cost and insurance coverage: paying $50, $99 or $1,349 per month

Wegovy: The manufacturer’s 2026 list price is $1,349.02 for a package of four pens, but real cost depends on insurance. Medicare’s GLP-1 Bridge program caps monthly cost at $50 for eligible beneficiaries through 2027, and commercial patients may use a $25 co-pay card if their plan covers the drug. (drugs.com)

Compounded semaglutide: A 2025 JAMA secret-shopper study found prices ranging $231–$330 per month across medical spas. (jamanetwork.com) The Rx.com weight loss program (compounded semaglutide from $99/month, tirzepatide from $149/month, online visit included) remains one of the lowest cash options, but remember these formulations are not FDA-approved.

Want the lowest pharmacy price for any prescription? Compare cash prices with a free Rx.com discount card before you pay.

How to decide between Wegovy and compounded semaglutide

Evidence vs budget: If you need the highest level of evidence and have insurance or Medicare coverage, Wegovy is the safer pick. If cost is your main barrier and you understand the extra risks, compounded semaglutide can be an interim option while you pursue insurance appeals or manufacturer assistance. Linking into our guide to choosing a safe GLP-1 provider can help you vet clinics.

Legal landscape: Because shortages are over, prescribers must document a legitimate medical need for compounding to stay compliant. Ask your clinic for that written justification.